Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1-Reference-Cited by-同舟云学术

Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1

Published:2023-05 Issue:5 Volume:103 Page:990-993
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Garrelfs Sander F.,Metry Elisabeth L.,van Harskamp Dewi,Vaz Frederic M.,van den Akker Chris H.P.,Schierbeek Henk,Groothoff Jaap W.,Oosterveld Michiel J.S.

Funder

Alnylam Pharmaceuticals

Stichting Metakids

Amsterdam UMC

Publisher

Elsevier BV

Subject

Nephrology

Reference6 articles.

1. Primary hyperoxaluria;Cochat;N Engl J Med,2013

2. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1;Garrelfs;N Engl J Med,2021

3. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria;Hoppe;Kidney Int,2022

4. Development and validation of a new gas chromatography-tandem mass spectrometry method for the measurement of enrichment of glyoxylate metabolism analytes in hyperoxaluria patients using a stable isotope procedure;van Harskamp;Anal Chem,2020

5. Endogenous oxalate production in primary hyperoxaluria type 1 patients;Garrelfs;J Am Soc Nephrol,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory;Kidney International Reports;2024-09

2. A molecular journey on the pathogenesis of primary hyperoxaluria;Current Opinion in Nephrology & Hypertension;2024-04-11

3. Lumasiran, Isolated Kidney Transplantation, and Continued Vigilance;New England Journal of Medicine;2024-03-14

4. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1;Kidney International Reports;2024-01

5. Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy;Kidney International;2023-07